Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Lantern Pharma Inc. (LTRN)

Compare
2.5800
-0.2300
(-8.19%)
At close: April 8 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
22,216.4370
22,216.4370
17,877.5700
14,432.7530
12,591.5080
Operating Income
-22,216.4370
-22,216.4370
-17,877.5700
-14,432.7530
-12,591.5080
Net Non Operating Interest Income Expense
742.3550
742.3550
765.3880
204.3550
67.9290
Other Income Expense
692.8690
692.8690
1,150.6480
-31.5480
160.5500
Pretax Income
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Net Income Common Stockholders
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Diluted NI Available to Com Stockholders
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Basic EPS
-1.93
--
-1.47
-1.31
-1.13
Diluted EPS
-1.93
--
-1.47
-1.31
-1.13
Basic Average Shares
10,762.3190
--
10,842.3650
10,850.5790
10,904.9270
Diluted Average Shares
10,762.3190
--
10,842.3650
10,850.5790
10,904.9270
Total Operating Income as Reported
-22,216.4370
-22,216.4370
-17,877.5700
-14,432.7530
-12,591.5080
Total Expenses
22,216.4370
22,216.4370
17,877.5700
14,432.7530
12,591.5080
Net Income from Continuing & Discontinued Operation
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Normalized Income
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Interest Income
742.3550
742.3550
765.3880
204.3550
67.9290
Net Interest Income
742.3550
742.3550
765.3880
204.3550
67.9290
EBIT
-22,216.4370
-22,216.4370
-17,877.5700
-14,432.7530
-12,591.5080
EBITDA
-22,199.1550
-22,199.1550
-17,862.9550
-14,422.6720
-12,584.7470
Reconciled Depreciation
17.2820
17.2820
14.6150
10.0810
6.7610
Net Income from Continuing Operation Net Minority Interest
-20,781.2130
-20,781.2130
-15,961.5340
-14,259.9460
-12,363.0290
Normalized EBITDA
-22,199.1550
-22,199.1550
-17,862.9550
-14,422.6720
-12,584.7470
12/31/2021 - 6/11/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers